ArticleAntibiotics (Basel, Switzerland)2023
Uncovering the Important Genetic Factors for Growth during Cefotaxime-Gentamicin Combination Treatment in
Article in Antibiotics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 9 citations in OpenAlex.
- Genome-wide identification of conditionally essential genes for growth in the presence of sulfamethoxazole and trimethoprim in sulfamethoxazole- and trimethoprim-resistantMicrobiology spectrum · 2026Article
- MappingAntibiotics (Basel, Switzerland) · 2026Article
- Genome-wide Screening of the Escherichia coli Keio Knockout Collection Identifies Genetic Determinants of Epetraborole Hypersusceptibility.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- Exploration of adverse event profiles for cefotaxime: a disproportionality analysis using the FDA adverse event reporting system.BMC pharmacology & toxicology · 2025Article
- Deletion of pcnB affects antibiotic susceptibility in resistant Escherichia coli by reducing copy number of ColE1-family plasmids.Scientific reports · 2025Article
- The Secondary Resistome of Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- The intrinsic macrolide resistome ofAntimicrobial agents and chemotherapy · 2024Article
- Genome-wide identification of fitness-genes in aminoglycoside-resistant Escherichia coli during antibiotic stress.Scientific reports · 2024Article
- Enhancing the Efficacy of Chloramphenicol Therapy forAntibiotics (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 3 countries.
Funding
Abstract
Due to the rapid spread of CTX-M type ESBLs, the rate of resistance to third-generation cephalosporin has increased among Gram-negative bacteria, especially in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.